IL-17-producing ST2<sup>+</sup> group 2 innate lymphoid cells play a pathogenic role in lung inflammation.

Cai, Ting; Qiu, Jinxin; Ji, Yan; Li, Wenjing; Ding, Zhaoyun; Suo, Caixia; Chang, Jiali; Wang, Jingjing et al. · J Allergy Clin Immunol · 2019

basic_science · Level V

Where this comes from

Abstract

IL-17 plays a pathogenic role in asthma. ST2<sup>-</sup> inflammatory group 2 innate lymphoid cells (ILC2s) driven by IL-25 can produce IL-17, whereas ST2<sup>+</sup> natural ILC2s produce little IL-17. We characterized ST2<sup>+</sup>IL-17<sup>+</sup> ILC2s during lung inflammation and determined the pathogenesis and molecular regulation of ST2<sup>+</sup>IL-17<sup>+</sup> ILC2s. Lung inflammation was induced by papain or IL-33. IL-17 production by lung ILC2s from wild-type, Rag1<sup>-/-</sup>, Rorc<sup>gfp/gfp</sup>, and aryl hydrocarbon receptor (Ahr)<sup>-/-</sup> mice was examined by using flow cytometry. Bone marrow transfer experiments were performed to evaluate hematopoietic myeloid differentiation primary response gene-88 (MyD88) signaling in regulating IL-17 production by ILC2s. mRNA expression of IL-17 was analyzed in purified naive ILC2s treated with IL-33, leukotrienes, and inhibitors for nuclear factor of activated T cells, p38, c-Jun N-terminal kinase, or nuclear factor κ light-chain enhancer of activated B cells. The pathogenesis of IL-17<sup>+</sup> ILC2s was determined by transferring wild-type or Il17<sup>-/-</sup> ILC2s to Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup> mice, which further induced lung inflammation. Finally, expression of 106 ILC2 signature genes was compared between ST2<sup>+</sup>IL-17<sup>+</sup> ILC2s and ST2<sup>+</sup>IL-17<sup>-</sup> ILC2s. Papain or IL-33 treatment boosted IL-17 production from ST2<sup>+</sup> ILC2s (referred to by us as ILC2<sub>17</sub>s) but not ST2<sup>-</sup> ILC2s. Ahr, but not retinoic acid receptor-related orphan receptor γt, facilitated the production of IL-17 by ILC2<sub>17</sub>s. The hematopoietic compartment of MyD88 signaling is essential for ILC2<sub>17</sub> induction. IL-33 works in synergy with leukotrienes, which signal through nuclear factor of activated T-cell activation to promote IL-17 in ILC2<sub>17</sub>s. Il17<sup>-/-</sup> ILC2s were less pathogenic in lung inflammation. ILC2<sub>17</sub>s concomitantly expressed IL-5 and IL-13 but expressed little GM-CSF. During lung inflammation, IL-33 and leukotrienes synergistically induce ILC2<sub>17</sub>s. ILC2<sub>17</sub>s are a highly pathogenic and unexpected source for IL-17 in lung inflammation.

Medical subject headings